0001493152-22-030274.txt : 20221103 0001493152-22-030274.hdr.sgml : 20221103 20221103070012 ACCESSION NUMBER: 0001493152-22-030274 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221103 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221103 DATE AS OF CHANGE: 20221103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Microbot Medical Inc. CENTRAL INDEX KEY: 0000883975 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943078125 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19871 FILM NUMBER: 221356095 BUSINESS ADDRESS: STREET 1: 25 RECREATION PARK DR SUITE 108 CITY: HINGHAM STATE: MA ZIP: 02043 BUSINESS PHONE: 908-938-5561 MAIL ADDRESS: STREET 1: 25 RECREATION PARK DR SUITE 108 CITY: HINGHAM STATE: MA ZIP: 02043 FORMER COMPANY: FORMER CONFORMED NAME: STEMCELLS INC DATE OF NAME CHANGE: 20000524 FORMER COMPANY: FORMER CONFORMED NAME: CYTOTHERAPEUTICS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2022

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware

000-19871

94-3078125

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

25 Recreation Park Drive, Unit 108

Hingham, Massachusetts 02043

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		MBOT		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On November 3, 2022, Microbot Medical Inc. (the “Company”) issued a press release announcing that it continues to aggressively protect its global intellectual property (IP) portfolio for the LIBERTY^® Robotic System as an additional patent allowance was issued by the Israeli Patent Office, covering the modular concept, and compliments a corresponding application that was previously granted by the U.S. Patent and Trademark Office (USPTO).

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description

99.1		Press Release dated November 3, 2022
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MICROBOT MEDICAL INC.

	By:	/s/ Harel Gadot
	Name:	Harel Gadot
	Title:	Chief Executive Officer, President and Chairman

Date: November 3, 2022

EX-99.1 2 ex99-1.htm

Exhibit 99.1

Microbot Medical Receives Additional Patent Allowance in Israel for the LIBERTY^® Robotic System

Corresponding Application Previously Granted in the U.S. as the Company Continues to Create Global Barriers to Entry for its Novel Technology

HINGHAM, Mass., November 3, 2022 – Microbot Medical Inc. (Nasdaq: MBOT) continues to aggressively protect its global intellectual property (IP) portfolio for the LIBERTY^® Robotic System as an additional patent allowance was issued by the Israeli Patent Office, covering the modular concept, and compliments a corresponding application that was previously granted by the U.S. Patent and Trademark Office (USPTO).

The allowed claims cover the unique modular and versatile design of the LIBERTY system allowing for the manipulation of a variety of tools. The Company expects the allowed claims to reinforce the position of LIBERTY as the first fully disposable, fully sterilized, robotic system for endovascular procedures.

“The impressive progress of the team is evident as we have now secured 5 patents for the LIBERTY Robotic System since it was unveiled just three years ago,” commented Harel Gadot, Chairman, CEO and President. “This level of success is incredibly important as we continue to progress the LIBERTY Robotic System, especially as we enter the regulatory phase and begin implementing the commercialization plan for our novel technology. We believe the LIBERTY Robotic System is going to dramatically change the landscape for endovascular procedures and to provide access for patients who have otherwise gone without proper treatment for lack of resources and access to advanced products.”

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.

Safe Harbor

Statements to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY and the One & Done^TM technologies, the outcome of its studies to evaluate LIBERTY, the One & Done^TM technologies and other existing and future technologies, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:

Michael Polyviou

EVC Group

mpolyviou@evcgroup.com

732-933-2754

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 mbot-20221010.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 mbot-20221010_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 mbot-20221010_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Nov. 03, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 03, 2022
Entity File Number	000-19871
Entity Registrant Name	MICROBOT MEDICAL INC.
Entity Central Index Key	0000883975
Entity Tax Identification Number	94-3078125
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	25 Recreation Park Drive
Entity Address, Address Line Two	Unit 108
Entity Address, City or Town	Hingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02043
City Area Code	(781)
Local Phone Number	875-3605
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	MBOT
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000883975 2022-11-03 2022-11-03 iso4217:USD shares iso4217:USD shares 0000883975 false 8-K 2022-11-03 MICROBOT MEDICAL INC. DE 000-19871 94-3078125 25 Recreation Park Drive Unit 108 Hingham MA 02043 (781) 875-3605 false false false false Common Stock, $0.01 par value MBOT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P M6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<- M!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:X1+_)UW M,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]Z MUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV, MIDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .; MO\P>=0>6N=6RKV' M5[+E&''\GN4/4$L#!!0 ( 4X8U4D'INBK0 /@! : >&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S M(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[. MXS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " %.&-599!YDAD! #/ P $P %M# M;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK M_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBN MM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F MI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S! M9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8 MYL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( 4X8U4' M04UB@0 +$ 0 " 0 !D;V-0&UL M4$L! A0#% @ !3AC57:,23SM *P( !$ ( !KP M &1O8U!R;W!S+V-O&UL4$L! A0#% @ !3AC59EH!EV,$ =$0 & @($," >&PO=V]R M:W-H965T&UL4$L! A0#% @ !3AC59^@&_"Q @ X@P M T ( !I0P 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ !3AC520>FZ*M ^ $ !H M ( !RA$ 'AL+U]R96QS+W=O9(9 0 SP, !, ( !KQ( %M# G;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ @ ^1, end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://microbotmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm mbot-20221010.xsd mbot-20221010_lab.xml mbot-20221010_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "mbot-20221010_lab.xml" ] }, "presentationLink": { "local": [ "mbot-20221010_pre.xml" ] }, "schema": { "local": [ "mbot-20221010.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "MBOT", "nsuri": "http://microbotmedical.com/20221010", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-11-03to2022-11-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://microbotmedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-11-03to2022-11-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-030274-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-030274-xbrl.zip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